California Public Employees Retirement System maintained its position in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 367,700 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. California Public Employees Retirement System owned approximately 0.23% of Navidea Biopharmaceuticals worth $188,000 at the end of the most recent quarter.

Separately, Vanguard Group Inc. increased its position in Navidea Biopharmaceuticals by 1.7% in the second quarter. Vanguard Group Inc. now owns 4,887,743 shares of the biopharmaceutical company’s stock worth $2,492,000 after purchasing an additional 80,499 shares during the last quarter.

Shares of Navidea Biopharmaceuticals Inc (NAVB) traded up $0.02 on Friday, reaching $0.44. 424,344 shares of the company traded hands, compared to its average volume of 495,817. Navidea Biopharmaceuticals Inc has a 12 month low of $0.29 and a 12 month high of $0.85.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. Navidea Biopharmaceuticals had a negative return on equity of 65.90% and a negative net margin of 515.33%. The business had revenue of $0.22 million during the quarter.

Separately, ValuEngine upgraded shares of Navidea Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at

Navidea Biopharmaceuticals Profile

Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.

Institutional Ownership by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Receive News & Stock Ratings for Navidea Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals Inc and related stocks with our FREE daily email newsletter.